Prothena to Cut Jobs, End Drug Trial After Missed Endpoints

Dow Jones

2025/05/24

By Katherine Hamilton

Prothena said it would reduce its workforce after a recent trial failed to meet its primary and secondary endpoints.

The Irish biotechnology company is planning a "substantial" job cut as it aims to decrease expenses, Chief Executive Daniel Welch said Friday. It is also evaluating business options, and will provide more details on the cuts in June, he said.

Prothena reported unfavorable data from a Phase 3 trial of birtamimab to treat the blood disorder AL amyloidosis. The study didn't meet its primary endpoint of time to all-cause mortality, the company said. The study also failed to meet the secondary endpoints of a 6-minute walk test distance and short-form-36 version 2 physical component score, Prothena said.

Due to the results, Prothena said it would end the trial.

Write to Katherine Hamilton at katherine.hamilton@wsj.com

(END) Dow Jones Newswires

May 23, 2025 16:25 ET (20:25 GMT)

应版权方要求，你需要登录查看该内容

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2537152321"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2537152321\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2537152321?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-24 04:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2537152321","market":"other","top_or_hot":-1,"title":"Prothena to Cut Jobs, End Drug Trial After Missed Endpoints","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Katherine Hamilton \n</p>\n<pre>\n \n</pre>\n<p>\n  Prothena said it would reduce its workforce after a recent trial failed to meet its primary and secondary endpoints. \n</p>\n<p>\n  The Irish biotechnology company is planning a \"substantial\" job cut as it aims to decrease expenses, Chief Executive Daniel Welch said Friday. It is also evaluating business options, and will provide more details on the cuts in June, he said. \n</p>\n<p>\n  Prothena reported unfavorable data from a Phase 3 trial of birtamimab to treat the blood disorder AL amyloidosis. The study didn't meet its primary endpoint of time to all-cause mortality, the company said. The study also failed to meet the secondary endpoints of a 6-minute walk test distance and short-form-36 version 2 physical component score, Prothena said. \n</p>\n<p>\n  Due to the results, Prothena said it would end the trial. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 23, 2025 16:25 ET (20:25 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Prothena to Cut Jobs, End Drug Trial After Missed Endpoints</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nProthena to Cut Jobs, End Drug Trial After Missed Endpoints\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-05-24 04:25</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Katherine Hamilton \n</p>\n<pre>\n \n</pre>\n<p>\n  Prothena said it would reduce its workforce after a recent trial failed to meet its primary and secondary endpoints. \n</p>\n<p>\n  The Irish biotechnology company is planning a \"substantial\" job cut as it aims to decrease expenses, Chief Executive Daniel Welch said Friday. It is also evaluating business options, and will provide more details on the cuts in June, he said. \n</p>\n<p>\n  Prothena reported unfavorable data from a Phase 3 trial of birtamimab to treat the blood disorder AL amyloidosis. The study didn't meet its primary endpoint of time to all-cause mortality, the company said. The study also failed to meet the secondary endpoints of a 6-minute walk test distance and short-form-36 version 2 physical component score, Prothena said. \n</p>\n<p>\n  Due to the results, Prothena said it would end the trial. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 23, 2025 16:25 ET (20:25 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PRTA","symbol_name":"Prothena Corporation plc","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2537152321","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2537152321","pubTimestamp":1748031900,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Prothena said it would reduce its workforce after a recent trial failed to meet its primary and secondary endpoints.The Irish biotechnology company is planning a \"substantial\" job cut as it aims to decrease expenses, Chief Executive Daniel Welch said Friday. It is also evaluating business options, and will provide more details on the cuts in June, he said.Prothena reported unfavorable data from a Phase 3 trial of birtamimab to treat the blood disorder AL amyloidosis. The study didn't meet its primary endpoint of time to all-cause mortality, the company said. The study also failed to meet the secondary endpoints of a 6-minute walk test distance and short-form-36 version 2 physical component score, Prothena said.Due to the results, Prothena said it would end the trial.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PRTA":"Prothena Corporation plc","BK4139":"生物科技"},"translate_title":"Prothena将裁员，在未达到终点后结束药物试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PRTA":0.9},"content_text":"By Katherine Hamilton \n\n\n \n\n\n  Prothena said it would reduce its workforce after a recent trial failed to meet its primary and secondary endpoints. \n\n\n  The Irish biotechnology company is planning a \"substantial\" job cut as it aims to decrease expenses, Chief Executive Daniel Welch said Friday. It is also evaluating business options, and will provide more details on the cuts in June, he said. \n\n\n  Prothena reported unfavorable data from a Phase 3 trial of birtamimab to treat the blood disorder AL amyloidosis. The study didn't meet its primary endpoint of time to all-cause mortality, the company said. The study also failed to meet the secondary endpoints of a 6-minute walk test distance and short-form-36 version 2 physical component score, Prothena said. \n\n\n  Due to the results, Prothena said it would end the trial. \n\n\n \n\n\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 23, 2025 16:25 ET (20:25 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"executive","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}